SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX) announced today that Eric K. Rowinsky, M.D., Chief Medical
Officer and Executive Vice President of ImClone Systems Incorporated, will
join its Board of Directors. In connection with Dr. Rowinsky's appointment,
ADVENTRX increased the size of its Board from six to seven directors.
"We are delighted to welcome Eric to our Board of Directors. He brings
tremendous knowledge and expertise within the oncology field," stated Evan
M. Levine, ADVENTRX's Chief Executive Officer and President. "We believe
his experience will be an important asset as we advance our product
candidates through the clinic," added Mr. Levine.
"I'm very pleased to be joining ADVENTRX's Board of Directors,"
commented Dr. Rowinsky. "I hope my contributions help advance the
development and commercialization of the Company's product candidates,
which hold significant potential to provide patients with better treatment
options."
Prior to joining ImClone Systems in 2005, Dr. Rowinsky focused his
academic efforts in cancer drug development as the Director of Clinical
Research and later Director of the Institute for Drug Development of the
Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair
for Early Drug Development from 1996 to 2005. He was also Clinical
Professor of Medicine in the Division of Medical Oncology at the University
of Texas Health Science Center at San Antonio from 1996 to 2006. From 1987
to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the
Johns Hopkins University School of Medicine. He was a longstanding NCI
principal investigator on U01 anticancer drug development grants and
integrally involved in pivotal clinical and preclinical investigations
which led to the development of paclitaxel, docetaxel, topotecan,
irinotecan, erlotinib and gefitinib, among others.
Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an
Associate Editor and/or Editorial Board Member of Cancer Research
(Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of
Oncology, Cancer Biology and Therapy and several other oncology journals
and has published over 270 manuscripts in both the preclinical and clinical
research fields. He has also served on the Scientific Advisory Board and
Project Advisory Boards of a large number of pharmaceutical and
biotechnology companies and has advised and/or presented aspects of New
Drug Applications to the FDA on several occasions. Dr. Rowinsky's honors
include receipt of the career development award of the American Cancer
Society and the 6th Annual Emil J. Freireich Award for outstanding
achievement of a young researcher in clinical cancer therapeutics. He also
served on the Board of Scientific Counselors of the National Cancer
Institute.
Dr. Rowinsky received his B.A. degree from New York University and his
M.D. from the Vanderbilt University School of Medicine. Following his
residency in internal medicine at the University of California, he
completed fellowship training in medical oncology at the Johns Hopkins
University School of Medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that ADVENTRX will be unable to raise sufficient
capital to fund the projects necessary to meet its anticipated or stated
goals and milestones; the risk that preclinical results are not indicative
of the success of subsequent clinical trials and the results of pending
clinical trials; the potential for ADVENTRX's product candidates to receive
regulatory approval for one or more indications on a timely basis or at
all, and the uncertain process of seeking regulatory approval; other
difficulties or delays in manufacturing, marketing and obtaining regulatory
approval for ADVENTRX's product candidates; the potential for regulatory
authorities to require additional preclinical work or other clinical
requirements to support regulatory filings; the market potential for
ADVENTRX's product candidates and ADVENTRX's ability to compete in those
markets; the scope and validity of patent protection for ADVENTRX's product
candidates; patent and non-patent exclusivity covering Navelbine(R) and
Taxotere(R); and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to update any forward-looking statement as set forth in this press
release to reflect events or circumstances arising after the date on which
it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866
|
